CABA News & Events

Cabaletta Bio and Cellares announced a commercial agreement to supply resecabtagene autoleucel using Cellares' automated Cell Shuttle and through future implementation of Cellares' Cell Q platform. The companies believe Cellares' automated platforms for manufacturing and QC release can enable flexible low-cost scaling of commercial production of rese-cel to thousands of batches per year with minimal capital investment. Under the agreement, Cellares is expected to provide future commercial supply of rese-cel, pending FDA approval, using its automated manufacturing and quality control platforms. Under the terms of the agreement, Cabaletta has secured the ability to supply thousands of batches per year over a 10-year period with minimal capital investment. The companies anticipate the per batch cost to be among the lowest in the industry for autologous cell therapy production.

Cabaletta Bio and Cellares announced a commercial agreement to supply rese-cel using Cellares' automated Cell Shuttle and through future implementation of Cellares' Cell Q platform. The Companies believe Cellares' automated platforms for manufacturing and QC release can enable flexible low-cost scaling of commercial production of rese-cel to thousands of batches per year with minimal capital investment. "Autoimmune diseases require a manufacturing infrastructure that operates at an order of magnitude greater scale than traditional oncology CAR T programs. This 10-year commercial agreement with Cabaletta reflects confidence in the Cell Shuttle and Cell Q platforms," said Fabian Gerlinghaus, Co-Founder and Chief Executive Officer, Cellares. "We look forward to continuing to support rese-cel's journey and helping potentially bring this treatment to many more patients."

Cellares announced that Cabaletta Bio Inc.'s investigational CAR T cell therapy rese-cel has been infused into the first two patients using drug product manufactured on Cellares' Cell Shuttle automated manufacturing platform. The administration of an autologous cell therapy, which met all release criteria and was manufactured on an automated manufacturing platform, represents an important step on the journey to realizing a future where scalable manufacturing of autologous products to supply thousands of patients per year can be achieved with minimal capital investment and a low cost of goods. "This is an important milestone that reflects focused collaboration between the teams at Cabaletta and Cellares since 2023," said Steven Nichtberger, M.D., Co-founder, Chairman, and Chief Executive Officer of Cabaletta Bio. "The dosing of these first two patients is an important demonstration of Cellares' GMP manufacturing and supply chain capabilities with their automated manufacturing platform and thus represents a significant achievement towards our goal of securing high-capacity flexible supply with minimal capital investment and a low cost of goods."